等位基因特异性小干扰RNA纠正KID综合征角质形成细胞异常表型
KID综合征是一种以眼、耳、皮肤异常为特征的严重不可治疾病,86%病例由GJB2基因杂合错义突变c.148G>A(p.D50N)引起。研究建立患者角质形成细胞系及人鼠嵌合皮肤移植模型,证实等位基因特异性小干扰RNA可抑制突变等位基因而不影响野生型表达,并纠正缝隙连接与半通道活性,为治疗提供概念验证。
要点
- KID综合征细胞模型显示缝隙连接通讯受损、半通道过度活跃。
- 等位基因特异性小干扰RNA选择性抑制突变GJB2等位基因,不改变野生型表达。
- 治疗纠正缝隙连接与半通道活性,全基因组RNA测序显示脱靶效应低。
核心结论
- 等位基因特异性小干扰RNA可纠正KID综合征角质形成细胞的异常细胞表型,为治疗KID综合征及其他显性遗传病提供概念验证。
研究设计与样本
- 从携带GJB2基因杂合p.D50N突变的KID综合征患者原代角质形成细胞建立细胞系(KID-KC)。
- 用该细胞系构建人鼠嵌合皮肤移植模型,模拟患者皮肤。
主要发现
- KID-KC显示缝隙连接通讯受损和半通道过度活跃,经染料转移、膜片钳和神经生物素摄取实验证实。
- 人鼠嵌合皮肤移植模型在体内模拟患者皮肤,证实KID-KC作为模型的有效性。
- 体外等位基因特异性小干扰RNA治疗强效抑制突变GJB2等位基因,不改变野生型等位基因表达。
- 治疗纠正缝隙连接和半通道活性,全基因组RNA测序检测到KID-KC中仅低水平脱靶效应。
临床怎么用
- 等位基因特异性小干扰RNA策略可能用于治疗KID综合征及其他显性遗传性皮肤病,但尚需进一步临床前和临床研究。
局限性
- 研究为体外细胞模型和动物模型的概念验证,尚未在患者中评估疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Keratitis-ichthyosis-deafness (KID) syndrome is a severe, untreatable condition characterized by ocular, auditory, and cutaneous abnormalities, with major complications of infection and skin cancer. Most cases of KID syndrome (86%) are caused by a heterozygous missense mutation (c.148G>A, p.D50N) in the GJB2 gene, encoding gap junction protein Cx26, which alters gating properties of Cx26 channels in a dominant manner. We hypothesized that a mutant allele-specific small interfering RNA could rescue the cellular phenotype in patient keratinocytes (KCs). A KID syndrome cell line (KID-KC) was established from primary patient KCs with a heterozygous p.D50N mutation. This cell line displayed impaired gap junction communication and hyperactive hemichannels, confirmed by dye transfer, patch clamp, and neurobiotin uptake assays. A human-murine chimeric skin graft model constructed with KID-KCs mimicked patient skin in vivo, further confirming the validity of these cells as a model. In vitro treatment with allele-specific small interfering RNA led to robust inhibition of the mutant GJB2 allele without altering expression of the wild-type allele. This corrected both gap junction and hemichannel activity. Notably, allele-specific small interfering RNA treatment caused only low-level off-target effects in KID-KCs, as detected by genome-wide RNA sequencing. Our data provide an important proof-of-concept and model system for the potential use of allele-specific small interfering RNA in treating KID syndrome and other dominant genetic conditions.
引用
- Lee MY, Wang HZ, White TW, et al. Allele-Specific Small Interfering RNA Corrects Aberrant Cellular Phenotype in Keratitis-Ichthyosis-Deafness Syndrome Keratinocytes. J Invest Dermatol. 2019. PMID: 31705875. doi:10.1016/j.jid.2019.09.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。